Fully-implantable CGM receives FDA authorization for integration with insulin pumps
The FDA granted integrated continuous glucose monitoring designation to a fully-implantable CGM, according to a press release. The Eversense E3 CGM (Senseonics Holdings and Ascensia Diabetes Care) received authorization to be marketed as an integrated CGM through the FDA’s De Novo pathway. The device is the first fully-implantable option in the category, according to the press release. The FDA